Overview

Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment

Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
0
Participant gender:
All
Summary
Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shandong University
Collaborators:
Binzhou People's Hospital
General Hospital of Jinan Military Region
Liaocheng People's Hospital
Shandong Provincial Hospital
Treatments:
Amoxicillin
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antitubercular
Bismuth
Clarithromycin
Furazolidone
Levofloxacin
Metronidazole
Ofloxacin
Proton Pump Inhibitors
Tetracycline
Tinidazole
Criteria
Inclusion Criteria:

- Consecutive patients who are 18-70 years old with persistent H. pylori infection after
first or second line treatment attempts.

Exclusion Criteria:

- Enable to undergo upper endoscopy;

- Patients with gastrectomy, acute GI bleeding and advanced gastric cancer;

- Known or suspected allergy to study medications;

- Taking bismuth and antibiotics in the previous four weeks, or taking proton pump
inhibitor and H2-receptor blockers in the previous two weeks;

- Currently pregnant or lactating

- Inability to provide informed consent and other situations that could interfere with
the examination or therapeutic protocol.